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Edited by Ivan SadowskiAbstract Posttranslational modiﬁcations of hypoxia-inducible
factor-1a (HIF-1a) inﬂuence HIF-mediated transcription, likely
by aﬀecting binding to p300/cAMP-response element-binding
protein (CBP). To systematically analyze the HIF-1a–p300/
CBP interaction, we developed a ﬂuorescence polarization-based
binding assay, employing ﬂuorescein-labeled peptides derived
from the C-terminal transactivation domain (C-TAD) of HIF-
1a. After optimized for eﬀectively capturing p300/CBP, the as-
say was utilized for evaluating direct eﬀects of posttranslational
modiﬁcations of the HIF-1a C-TAD on p300 binding. The
results demonstrated that asparagine hydroxylation and S-nitro-
sylation of HIF-1a decrease p300 binding, while its phosphoryla-
tion does not aﬀect p300 binding, which was reconﬁrmed by
competitive inhibition analyses using mutant peptides.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mammalian cells possess the ability to sense and respond to
a local decrease in oxygen levels, mediated by hypoxia-induc-
ible factor-1 (HIF-1) [1]. Under hypoxic conditions, inducible
HIF-1a is accumulated in the nucleus where it dimerizes with
constitutive HIF-1b, which subsequently activates transcrip-
tion of target genes [2]. Full transcriptional activity of HIF-1
requires the additional interaction of the C-terminal trans-
activation domain (C-TAD) of HIF-1a with the cysteine/
histidine-rich 1 (CH1) domain of the coactivators p300 and
cAMP-response element-binding protein (CBP) [3,4].
In normoxia, proline hydroxylation of HIF-1a signals binding
of the von Hippel-Lindau protein (VHL), leading to HIF-1a
destruction [5,6]. TheHIF-1a–VHL complex further recruits fac-
tor inhibiting HIF-1a (FIH-1), which hydroxylates Asn-803 inAbbreviations: CBP, cAMP-response element-binding protein; CK2,
casein kinase 2; C-TAD, C-terminal transactivation domain; FIH-1,
factor inhibiting HIF-1a; FP, ﬂuorescence polarization; HIF, hypoxia-
inducible factor; VHL, von Hippel-Lindau protein
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doi:10.1016/j.febslet.2007.03.015the C-TAD of HIF-1a, thereby disrupting its interaction with
p300/CBP and blocking the HIF-mediated transactivation [7].
In addition to asparagine hydroxylation, other posttranslational
modiﬁcations of residues in C-TAD have been proposed to inﬂu-
ence the ﬁne-tuning of HIF-1a function [8]. S-Nitrosylation of
Cys-800 in HIF-1a has been shown to increase HIF-1 transcrip-
tional activity possibly by enhancing its p300 binding [9], while
some conﬂicting eﬀects of nitric oxide on hypoxia-induced trans-
activation have been reported [10]. Phosphorylation of HIF-1a
can also modulate its transcriptional activity. The hypoxia-in-
duced activation of mitogen-activated protein kinase has been
suggested to phosphorylate HIF-1a, which appears to increase
its p300 binding but is not correlated with its transcriptional
activity [11]. However, the phosphorylation sites responsible for
HIF-1a nuclear accumulation have been identiﬁed to reside far
from the C-TAD [12]. On the other hand, Thr-796 in C-TAD
has been indicated as a candidate for phosphorylation possibly
by casein kinase 2 (CK2) [13]. Despite the abundance of tran-
scription activity data aﬀected by posttranslationalmodiﬁcations
of the HIF-1a C-TAD, scattered information is available for the
direct eﬀects of such modiﬁcations on its p300/CBP binding.
We have previously developed a HIF–VHL interaction as-
say, which could be utilized for monitoring prolyl hydroxyl-
ation [14]. Here, we have employed ﬂuorescein-labeled
peptides derived from the C-TAD to set up a similar ﬂuores-
cence polarization (FP)-based binding assay, which has been
utilized for systematically evaluating the HIF–p300/CBP inter-
action, and examining the eﬀects of post-translational modiﬁ-
cations of the C-TAD peptide on p300 binding.2. Materials and methods
2.1. Materials
S-Nitroso-N-acetylpenicillamine (SNAP), Sephadex-G15, and
thrombin were purchased from Sigma–Aldrich (St. Louis, USA),
CK2 from New England Biolabs (Beverly, USA), and streptavidin
from Calbiochem (Darmstadt, Germany). To prepare a biotinylating
reagent for quantiﬁcation of S-nitrosylation, biotin-Cys-NH2 was syn-
thesized on Rink Amide resin (NovaBiochem) using Fmoc-Cys
(25 lmol), followed by addition of 12 mg 1,11-bis-maleimidotriethyl-
eneglycol (Pierce) to the 1.5 ml solution of biotin-Cys-NH2 (4 mg) in
PBS/DMSO (1:2 vol/vol). After the mixture was stirred at room tem-
perature overnight, the biotinylating reagent was puriﬁed by reverse-
phase HPLC, and characterized by MALDI-TOF mass spectrometry.
2.2. Peptide preparation
Fluorescein-labeled peptides containing the C-TAD of human HIF-
1a were synthesized by conjugating ﬂuorescein with the N-terminal
insertion of an aminocaproic acid linker (AnyGen, KwangJu, Korea).blished by Elsevier B.V. All rights reserved.
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822, and 776–813 were denoted as F-HIF-1a-(776–826), F-HIF-1a-
(786–826), F-HIF-1a-(788–822), and F-HIF-1a-(776–813), respectively.
For mutant peptides, human HIF-1a-(786–826) and its single muta-
tion products prepared by PCR were subcloned into pGEX-2T-1
(Amersham Biosciences) and overexpressed in E. coli BL21(DE3).
After puriﬁcation of the GST fusion proteins using glutathione–Se-
pharose (Amersham Biosciences) and GST removal by thrombin treat-
ment, the resulting peptides were puriﬁed using reverse-phase HPLC
and conﬁrmed by MALDI-TOF mass spectrometry.
2.3. Protein expression and puriﬁcation
The truncated human CBP (amino acids 1–450) subcloned in pGEX-
KG, and the truncated human p300 (amino acids 300–520) and the
full-length human FIH-1 (amino acids 1–349) subcloned in pGEX-
4T-1 (Amersham Biosciences) and pET-28a (Novagen), respectively,
were overexpressed in E. coli BL21(DE3). GST-CBP and GST-p300
were puriﬁed on glutathione-Sepharose, and His-FIH-1 on Ni-NTA
agarose (Qiagen). The puriﬁed fusion proteins were conﬁrmed by
SDS–PAGE and quantiﬁed by Bradford assay (Bio-Rad).
2.4. Asparagine hydroxylation by FIH-1
Five micromolar F-HIF-1a-(786–826) was incubated with recombi-
nant His-FIH-1 (0.7 lg/lL) in hydroxylation reaction buﬀer (20 mM
Tris–HCl, pH 7.5, 5 mM KCl, 1.5 mM MgCl2) containing 400 lM
ascorbic acid and 100 lM a-ketoglutarate. After incubation for 2 h at
room temperature, the reaction mixture was passed through ZipTipC18
(Millipore, USA) for desalting, followed by elution by adding a-cyano-
4-hydroxycinnamic acid in acetonitrile/water containing 0.1% TFA
(1:1 vol/vol). The eluted peptide solution was then transferred to a
MALDI sample plate andMALDI-TOFmeasurements were performed
with a Voyager analyzer (Applied Biosystems). For binding assays, the
hydroxylated peptide was puriﬁed by reverse-phase HPLC.
2.5. S-Nitrosylation by SNAP
Thirty micromolar F-HIF-1a-(786–826) and F-HIF-1a-(786–
826)[C800A] containing Ala substitution for Cys were incubated with
2 mM SNAP in 50 mM Tris, pH 8.0 for 30 min at 30 C. After excess
SNAP was removed using a Sephadex G-15 resin, S-nitrosylation of
the peptide was determined by absorbance measurements of the nitro-
sothiol moiety [15], or by FP measurements upon addition of strepta-
vidin to the peptides reacted with the biotinylating reagent (300 lM)
for 2 h at room temperature. The S-nitrosylated peptide was obtained
by separating from the biotinylated one on reverse-phase HPLC for
binding assays.
2.6. Phosphorylation with kinases
Phosphorylation reactions were performed with CK2 (500 U) in
50 lL of kinase reaction buﬀer (25 mM HEPES, pH 7.5, 20 mMFP
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Fig. 1. Eﬀects of Zn2+ in the preparation of p300/CBP proteins on their intera
CBP and GST-p300 preparations, 0.1 mM ZnSO4 was omitted or included eit
measured for (A) F-HIF-1a-(776–826) at 100 nM incubated with or without
with or without 800 nM GST-p300.MgCl2, 2 mM DTT, 0.1 mM Na3VO4) containing 100 lM ATP with
or without [c-32P] ATP using 3 lM F-HIF1a-(786–826) or F-HIF1a-
(788–822) as substrates for 30 min at room temperature for radioactive
assays, or for 3 h at 30 C for MALDI-TOF analysis. For binding as-
says, the phosphorylated product was puriﬁed by reverse-phase HPLC
after the reaction at room temperature overnight.
2.7. Binding assays
Fluorescein-labeled peptides (100 nM) were mixed with GST-CBP
or GST-p300 in EBC buﬀer (50 mM Tris, pH 8.0, 120 mM NaCl,
and 0.25% Nonidet P40) at room temperature, followed by FP mea-
surements using an LS50B ﬂuorimeter (Perkin-Elmer). Representative
binding data of at least duplicate assays are shown in ﬁgures where er-
ror bars are omitted since they are within the symbol points, and the
data for at least three independent experiments were analyzed using
KaleidaGraph software as described previously [14].3. Results and discussion
3.1. FP-based measurements of the interaction of HIF-1a
peptides with p300/CBP
The CH1 domain of p300/CBP that interacts with HIF-1a is
stabilized by Zn2+-binding while the metal-free CH1 is disor-
dered [16]. Therefore, the importance of Zn2+ in p300/CBP
preparations was ﬁrst tested for their binding to the HIF-1a-
derived peptides by preparing GST-p300 and GST-CBP
proteins in the absence or presence of ZnSO4. For the binding
assays, ﬂuorescein-labeled F-HIF-1a-(786–826) and F-HIF-
1a-(776–826) were utilized for GST-p300 and GST-CBP,
respectively, since the C-terminal 41 residues 786–826 appear
to be important for p300 binding [7], and the 51 residues
776–786 for CBP binding [17]. Due to the size diﬀerence, FP
of F-HIF-1a-(776–826) (Fig. 1A) was higher than that of F-
HIF-1a-(786–826) (Fig. 1B). Addition of GST-CBP (Fig. 1A)
and GST-p300 (Fig. 1B) to the peptides increased FP signiﬁ-
cantly to the similar values irrespective of the ZnSO4 inclusion
in protein preparations, indicating that Zn2+ in the culture
media is present enough to complex with the recombinant pro-
teins. Since excess Zn2+ might induce misfolding of p300/CBP
[18], ZnSO4 was excluded in p300/CBP preparations. It should
be noted that GST incubated with the ﬂuorescein-labeled
peptides did not show any change in FP (data not shown),
conﬁrming no non-speciﬁc binding.FP
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tides derived from HIF-1a C-TAD with p300/CBP. Since these
peptides exhibited size-dependent basal FP values, net changes
of FP values are presented in Fig. 2. In the case of CBP, FP
values of F-HIF-1a-(776–826) and F-HIF-1a-(786–826) in-
creased and plateaued with increasing GST-CBP concentra-
tions (Fig. 2A). Although the residues 776–790 of HIF-1a,B
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and of 198 ± 23 nM for F-HIF-1a-(786–826). On the other
hand, FP of F-HIF-1a-(788–822) increased much less, while
F-HIF-1a-(776–813) showed no FP increase up to 3 lM
GST-CBP (Fig. 2A). In accordance with these results, the res-[p300] (nM)
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Fig. 4. S-Nitrosylation of HIF-1a. 30 lM F-HIF-1a-(786–826) was
incubated with 2 mM SNAP for 30 min at 30 C, and excess SNAP
was removed by gel ﬁltration. (A) The presence of the nitrosothiol
bond was conﬁrmed by measuring absorbance of the peptide treated
with (solid line) or without SNAP (dotted line). (B) Wild-type (WT)
and C800A F-HIF-1a-(786–826) peptides pretreated with or without
SNAP were incubated with or without the biotinylating reagent for 2
hr at room temperature, puriﬁed by reverse-phase HPLC, and
measured for FP in the presence of 250 nM streptavidin. (C) F-HIF-
1a-(786–826) (d), S-nitrosylated F-HIF-1a-(786–826) (j), and F-HIF-
1a-(786–826)[C800A] (m) at 100 nM were mixed with increasing
concentrations of GST-p300 in EBC buﬀer, followed by FP measure-
ments.
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p300/CBP binding as well as for HIF-1a-mediated transactiva-
tion [19]. Similarly, FP values of F-HIF-1a-(776–826) and
F-HIF-1a-(786–826) increased with increasing GST-p300 con-
centrations (Fig. 2B). The dissociation constants were deter-
mined to be 189 ± 45 nM for F-HIF-1a-(776–826) and
166 ± 66 nM for F-HIF-1a-(786–826). In addition, FP of F-
HIF-1a-(788–822) increased only slightly and that of F-HIF-
1a-(776–813) did not change with increasing GST-p300
(Fig. 2B), again indicating the critical role of the C-TAD C-ter-
minal helix in p300 binding, consistent with the report that
Leu-818, Leu-819 and Leu-822 contribute to the hydrophobic
core of HIF-1a–p300 complex, and Asp-823 interacts electro-
statically with the CH1 domain of p300 [20]. These results
demonstrated that the simple FP-based analyses using the ﬂuo-
rescein-labeled peptides enable quantitative evaluations of
peptide fragments derived from the HIF-1a C-TAD for
p300/CBP binding activities.
3.2. Eﬀect of hydroxylation by FIH
Hydroxylation of Asn-803 prevents the HIF-1 transcrip-
tional activation by inhibiting recruitment of p300/CBP by
HIF-1a [8]. Therefore, we investigated the direct hydroxylation
eﬀect on p300 binding employing the developed FP-based as-
say. We decided to use GST-p300 because of its larger size
and bigger changes in FP upon binding to the ﬂuorescein-la-
beled peptide, resulting in more reliable data. Hydroxylation
by recombinant His-FIH-1 was ﬁrst assessed by MALDI-
TOF analysis for F-HIF-1a-(786–826) which contains the res-
idues for p300 binding activity (Fig. 2B) as well as full FIH-1
activity [21]. As shown in Fig. 3A, His-FIH-1 treatment of the
peptide yielded an increase of a mass of 16 Da compared to
the control (Fig. 3A), conﬁrming asparagine hydroxylation.
The puriﬁed, hydroxylated F-HIF-1a-(786–826) was then used
to monitor FP changes upon mixing with GST-p300 since
ascorbic acid and a-ketoglutarate included in the hydroxyl-
ation reaction could interfere with the HIF-1a–p300 interac-
tion and FP measurements. FP of the hydroxylated peptide
increased with increasing p300 concentrations to a much lesser
degree than that of the unmodiﬁed peptide (Fig. 3B). We there-
fore concluded that asparagine hydroxylation of HIF-1a by
FIH-1 abrogates, albeit not fully, p300 binding activity.
3.3. Eﬀect of S-nitrosylation
S-Nitrosylation on Cys-800 of HIF-1a has been reported to
increase the p300 recruitment and transcriptional activity
whereas nitric oxide has been shown to increase or decrease
HIF-1a stability [9,10]. Thus, we evaluated the eﬀect of S-nit-
rosylation of Cys-800 in HIF-1a on its p300 binding. Since the
nitrosothiol bond could not be detected by MALDI-TOF
analysis due to its laser-induced dissociation, the nitrosothiol
bond formation was detected by the absorbance at 320 nm,
which was present in the SNAP-treated F-HIF-1a-(786–826)
but absent in the untreated peptide (Fig. 4A) when the peptide
amounts were normalized to the ﬂuorescein absorption peaks.
We additionally devised a biotinylation method for detecting
and purifying S-nitrosylated peptides by modifying the previ-
ously reported method [15]. Because F-HIF-1a-(786–826) has
only one cysteine Cys-800, the S-nitrosylated peptide cannot
be biotinylated whereas free cysteine in the untreated peptide
is biotinlyated when F-HIF-1a-(786–826) treated with or with-out SNAP was reacted with the synthesized biotinylating re-
agent. This biotinylation allowed FP changes upon
streptavidin binding, and facilitated puriﬁcation of the S-nitro-
sylated peptide since the S-nitrosylated peptide was readily
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iﬁed one by reverse-phase HPLC. As shown in Fig. 4B, strep-
tavidin addition increased FP of the biotinylated peptide, but
did not change FP of the S-nitrosylated peptide which could
not be modiﬁed with the biotinylating reagent. Moreover,
when the mutant F-HIF-1a-(786–826)[C800A] peptide con-
taining Ala substitution for Cys-800 was treated with SNAP,
followed by biotinylation, FP did not change (Fig. 4B) as ex-
pected.
After S-nitrosylation of Cys-800 in F-HIF-1a-(786–826) was
conﬁrmed, its eﬀects on p300 binding was investigated. When
S-nitrosylated and untreated F-HIF-1a-(786–826), and F-
HIF-1a-(786–826)[C800A] mixed with GST-p300 were ana-
lyzed for FP, both F-HIF-1a-(786–826)[C800A] and untreated
F-HIF-1a-(786–826) exhibited similar concentration-depen-
dent binding patterns, while S-nitrosylated F-HIF-1a-(786–
826) showed only minimal increase in FP with increasingp300 concentrations (Fig. 4C). Our data clearly showed that
S-nitrosylation of HIF-1a dramatically inhibits its p300 bind-
ing, which is contrary to the previous report that treatment
with a nitrosylating reagent appeared to enhance HIF-1a
pulled down by GST-CH1 [9]. Since Cys-800 is deeply buried
in the molecular interface in the p300–HIF-1a complex as re-
vealed by structural studies [17,20], it is reasonable to postulate
that introduction of a polar NO group to Cys-800 would easily
disrupt the p300–HIF-1a interaction.
3.4. Eﬀect of phosphorylation
Thr-796 in HIF-1a has been suggested to be phosphorylated,
thereby enhancing the HIF-1a–CBP interaction [22], although
phosphorylation sites of HIF-1a far from the C-TAD have
been identiﬁed [12]. Accordingly, we used a direct binding as-
say to examine the eﬀect of phosphorylation of F-HIF-1a-
(786–826) on p300 binding activity. Radioactive assays were
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Fig. 6. Competitive inhibition analyses for HIF-1a peptides with point
mutations on the HIF-1a–p300 interaction. Wild-type (d), T796D (j),
N803A (s), and C800S (h) HIF-1a-(786–826) peptides were added to
the mixture containing 100 nM F-HIF-1a-(786–826) and 800 nM
GST-p300 in EBC buﬀer, and their competitive binding was measured
by FP.
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out CK2 to show phosphorylation of the peptide (Fig. 5A).
In addition, MALDI-TOF analysis yielded a new peak corre-
sponding to a mass increase of 80 Da (Fig. 5C), indicating
mono-phosphorylation of the peptide. Since both Ser-786
and Thr-796 are putative CK2 phosphorylation sites [13], F-
HIF-1a-(788–822) lacking Ser-786 was used to demonstrate
mono-phosphorylation by CK2 as determined by MALDI-
TOF analysis (Fig. 5D). These results implied that only Thr-
796 was phosphorylated CK2. When the CK2-phosphorylated
peptide was puriﬁed and examined for p300 binding by FP
measurements, the phosphorylated peptide exhibited a similar
p300 binding pattern to the untreated peptide (Fig. 5B). There-
fore, phosphorylation of C-TAD in HIF-1a unlikely aﬀects the
HIF-1a–p300 interaction, but may increase HIF transcrip-
tional activity possibly by decreasing its aﬃnity for FIH-1 [23].
3.5. Competitive binding analyses
To compare the importance of Thr-796, Cys-800 and Asn-
803 residues of the HIF-1a peptide on p300 binding activity,
we performed competitive inhibition analyses of the FP-based
binding assays using single mutant peptides. Fig. 6 shows FP
assay data for the mixtures of GST-p300 and F-HIF-1a-
(786–826) containing varying concentrations of wild-type and
single mutant peptides. While the wild-type peptide with resi-
dues 786–826 of HIF-1a eﬀectively competed with F-HIF-
1a-(786–826) for the p300 binding (Ki of 319 ± 60 nM), the
C800S mutant peptide was a poor inhibitor (Ki of
3592 ± 560 nM). This is consistent with the previous report
that hydrophilic substitutions of Cys-800 in HIF-1a with Ser
or Asp disturb p300 binding, but hydrophobic substitutions
with Ala or Val do not [24], which was also shown by the
p300 binding results using F-HIF-1a-(786–826)[C800A]
(Fig. 4C). On the other hand, T796D and N803A mutants
competitively inhibited the p300 binding to F-HIF-1a-(786–
826) to a little lesser degree than the wild-type (Fig. 6). These
results indicated that mutation of Asn-803 to Ala has little ef-
fects in p300 binding but abolishes hydroxylation by FIH-1
(data not shown), and also conﬁrms that phosphorylation of
Thr-796 does not play a signiﬁcant role in p300 binding. Inconclusion, the results presented here resolved some conﬂicting
issues of the eﬀects of posttranslational modiﬁcations on p300
binding activity, although such eﬀects might be exerted to
HIF-mediated transcription via some other mechanisms rather
than direct modulations of the HIF-1a–p300 binding.
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